These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449 [TBL] [Abstract][Full Text] [Related]
8. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation. Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275 [TBL] [Abstract][Full Text] [Related]
9. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755 [TBL] [Abstract][Full Text] [Related]
11. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients. Royston L; Royston E; Masouridi-Levrat S; Chalandon Y; Van Delden C; Neofytos D Immun Inflamm Dis; 2021 Sep; 9(3):771-776. PubMed ID: 33949798 [TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis. Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206 [TBL] [Abstract][Full Text] [Related]
13. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant. Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623 [TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study. Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290 [TBL] [Abstract][Full Text] [Related]
15. Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease. Wolfe D; Zhao Q; Siegel E; Puto M; Murphy D; Roddy J; Efebera Y; Tossey J Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771734 [TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies. Vyas A; Raval AD; Kamat S; LaPlante K; Tang Y; Chemaly RF Open Forum Infect Dis; 2023 Jan; 10(1):ofac687. PubMed ID: 36726548 [TBL] [Abstract][Full Text] [Related]
17. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir. Giménez E; Guerreiro M; Torres I; Aguilar C; Albert E; Hernández-Boluda JC; Hernani R; Pérez A; Amat P; Piñana JL; Montoro J; Solano C; Navarro D Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748 [TBL] [Abstract][Full Text] [Related]
18. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841 [TBL] [Abstract][Full Text] [Related]
19. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. Foolad F; Aitken SL; Chemaly RF Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790 [TBL] [Abstract][Full Text] [Related]
20. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis. Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]